Tech Company M&A Transactions
Alvine Pharmaceuticals Acquisition
On 3/16/2016, Alvine Pharmaceuticals was acquired by ImmunogenX. What ImmunogenX paid for Alvine Pharmaceuticals was not provided.
Transaction Overview
Company Name
Acquired By
Announced On
3/16/2016
Transaction Type
M&A
Amount
Unknown
M&A Terms
The asset acquired was Latiglutenase (formerly known as ALV003 and renamed IMGX-003), an orally administered mixture of two recombinant gluten-specific proteases that degrades gluten proteins into small physiologically irrelevant fragments.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
75 Shoreway Rd. B
San Carlos, CA 94070
USA
San Carlos, CA 94070
USA
Phone
Website
Email Address
Not Recorded
Overview
Alvine Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutics for the treatment of Celiac sprue.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Abhay Joshi
Chief Medical Officer
Daniel Adelman
VP - Finance
David Southern
VP - Marketing
Kirk Essenmacher
VP - Regulatory Affairs
Henk Kocken
VP - Sales
James Watson
Browse more venture capital transactions:
Prev: 3/16/2016: Marley Spoon venture capital transaction
Next: 3/16/2016: Endgame venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs